Current treatment options for hyperprolactinemia

被引:15
作者
Faje, Alexander [1 ]
Nachtigall, Lisa [2 ]
机构
[1] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Neuroendocrine Clin Ctr, Boston, MA 02114 USA
关键词
dopamine agonist; hyperprolactinemia; prolactinoma; PLASMA PROLACTIN CONCENTRATIONS; ENDOTHELIAL GROWTH-FACTOR; SOMATOSTATIN RECEPTOR SUBTYPES; SECRETING PITUITARY-ADENOMAS; METASTATIC BREAST-CANCER; DOPAMINE AGONIST THERAPY; REPAIR PROTEIN MSH6; TRANSSPHENOIDAL SURGERY; CABERGOLINE TREATMENT; NATURAL-HISTORY;
D O I
10.1517/14656566.2013.806488
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Hyperprolactinemia is a prevalent cause of oligo-amenorrhea, and prolactinomas are the most common type of functional pituitary tumor. Untreated hyperprolactinemia can lead to bone loss and impair gonadal function and fertility. Normalization of prolactin improves bone mass and restores gonadal function in a majority of patients. Areas covered: This article contains an overview of hyperprolactinemia with an emphasis on pharmacologic, surgical and radiation treatment options. Discussion focuses on the efficacy and safety of available treatments and comments on new and emerging therapies. Expert opinion: Dopamine agonists, usually cabergoline, remain the primary choice for initial treatment of hyperprolactinemia. Surgery may also be an appropriate alternative in certain circumstances. Monotherapy with dopamine agonists is often successful at controlling prolactin levels and tumor size, but adjunctive treatments may be necessary for resistant or aggressive prolactinomas.
引用
收藏
页码:1611 / 1625
页数:15
相关论文
共 189 条
  • [1] Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice
    Asa, SL
    Kelly, MA
    Grandy, DK
    Low, MJ
    [J]. ENDOCRINOLOGY, 1999, 140 (11) : 5348 - 5355
  • [2] Hypoadiponectinemia in lean lactating women: Prolactin inhibits adiponectin secretion from human adipocytes
    Asai-Sato, Mikiko
    Okamoto, Machi
    Endo, Masaya
    Yoshida, Hiroshi
    Murase, Mariko
    Ikeda, Mario
    Sakakibara, Hideya
    Takahashi, Tsuneo
    Hirahara, Fumiki
    [J]. ENDOCRINE JOURNAL, 2006, 53 (04) : 555 - 562
  • [3] Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas
    Athanasoulia, A. P.
    Sievers, C.
    Ising, M.
    Brockhaus, A. C.
    Yassouridis, A.
    Stalla, G. K.
    Uhr, M.
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (03) : 327 - 335
  • [4] Results of a Single-Center Observational 10-Year Survey Study on Recurrence of Hyperprolactinemia after Pregnancy and Lactation
    Auriemma, Renata S.
    Perone, Ylenia
    Di Sarno, Antonella
    Grasso, Ludovica F. S.
    Guerra, Ermelinda
    Gasperi, Maurizio
    Pivonello, Rosario
    Colao, Annamaria
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (01) : 372 - 379
  • [5] First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment
    S. Baldari
    F. Ferraù
    C. Alafaci
    A. Herberg
    F. Granata
    V. Militano
    F. M. Salpietro
    F. Trimarchi
    S. Cannavò
    [J]. Pituitary, 2012, 15 (Suppl 1) : S57 - S60
  • [6] Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: Mortality, morbidity, and the effects of hospital and surgeon volume
    Barker, FG
    Klibanski, A
    Swearingen, B
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10) : 4709 - 4719
  • [7] The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor
    Basu, S
    Nagy, JA
    Pal, S
    Vasile, E
    Eckelhoefer, IA
    Bliss, VS
    Manseau, EJ
    Dasgupta, PS
    Dvorak, HF
    Mukhopadhyay, D
    [J]. NATURE MEDICINE, 2001, 7 (05) : 569 - 574
  • [8] Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review
    Behan, L. A.
    Draman, M. S.
    Moran, C.
    King, T.
    Crowley, R. K.
    O'Sullivan, E. P.
    Smith, D.
    Thompson, C. J.
    Agha, A.
    [J]. PITUITARY, 2011, 14 (04) : 362 - 366
  • [9] What can we learn from rodents about prolactin in humans?
    Ben-Jonathan, Nira
    LaPensee, Christopher R.
    LaPensee, Elizabeth W.
    [J]. ENDOCRINE REVIEWS, 2008, 29 (01) : 1 - 41
  • [10] BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639